A
Allotex
Offers therapeutic solutions for the treatment of presbyopia and hyperopia
About Allotex
Allotex, Inc. is a pioneering startup in the field of ophthalmology, specializing in minimally invasive vision correction using allograft tissue. Founded in 2014 by Dr. David Muller, a notable figure in the field of laser vision correction, and joined by Prof. Michael Mrochen in 2015, the company focuses on providing solutions for patients suffering from presbyopia and hyperopia. Allotex operates in the medical device market, specifically targeting ophthalmic treatments. The company's core product is a tissue addition technology that allows for vision correction by placing implants just beneath the surface of the eye, making the procedure less invasive compared to traditional methods. Allotex serves patients seeking advanced vision correction solutions and collaborates with ophthalmologists and eye care clinics to deliver its innovative treatments. The business model revolves around the development, approval, and commercialization of its proprietary technology, generating revenue through the sale of its medical devices and related services.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2008
- Headquarters
- Milan, Italy
- Employees
- 30
- Open positions
- None listed
- Dealroom signal
- 90.5/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| GROWTH EQUITY VC✓Equity / VC | Nov 2023 | $0 | — | Junson Capital | ↗ |
| SERIES B✓Equity / VC | Jul 2023 | $30M | $120M | Panakès Partners · Supernova Invest · KCK MedTech · Exor Ventures | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Allotex is 1.8K monthly website visits, up 150% over the last three months. Allotex's team grew 20% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
KCK MedTech
Panakès Partners
Supernova Invest
Exor Ventures
Series B and later1 investor entered at this stage
Junson Capital
Other known investors1 additional known investor
Ora Global
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Allotex on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Allotex’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.